These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27704665)

  • 1. Predictive parameter of tolvaptan effectiveness in cirrhotic ascites.
    Kawaratani H; Fukui H; Moriya K; Noguchi R; Namisaki T; Uejima M; Kitade M; Takeda K; Okura Y; Kaji K; Nishimura N; Takaya H; Aihara Y; Sawada Y; Sato S; Seki K; Mitoro A; Yamao J; Yoshiji H
    Hepatol Res; 2017 Aug; 47(9):854-861. PubMed ID: 27704665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites.
    Shigefuku R; Iwasa M; Eguchi A; Tempaku M; Tamai Y; Suzuki T; Takei Y
    Intern Med; 2021; 60(21):3359-3368. PubMed ID: 34719623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites.
    Kogiso T; Yamamoto K; Kobayashi M; Ikarashi Y; Kodama K; Taniai M; Torii N; Hashimoto E; Tokushige K
    Hepatol Res; 2017 Aug; 47(9):835-844. PubMed ID: 27670393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily Monitoring of Serum Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein Is Useful for Predicting Therapeutic Effect of Tolvaptan in Cirrhotic Ascites.
    Takamura M; Sakamaki A; Arao Y; Setsu T; Kamimura H; Yokoo T; Kamimura K; Tsuchiya A; Terai S
    Tohoku J Exp Med; 2020 Dec; 252(4):287-296. PubMed ID: 33208569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis.
    Akiyama S; Ikeda K; Sezaki H; Fukushima T; Sorin Y; Kawamura Y; Saitoh S; Hosaka T; Akuta N; Kobayashi M; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Hepatol Res; 2015 Nov; 45(11):1062-70. PubMed ID: 25429910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genome-wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites.
    Kawaratani H; Sawai H; Onishi M; Kogiso T; Shimada N; Uojima H; Nakajima T; Matsumoto N; Ikejima K; Ishikawa T; Terai S; Motoyama H; Komori A; Hirashima N; Saito S; Eguchi Y; Nojima M; Kawai Y; Tateyama M; Yoshiji H; Tanaka Y
    Liver Int; 2021 Dec; 41(12):2944-2953. PubMed ID: 34309184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.
    Shiba S; Chu PS; Nakamoto N; Yamataka K; Taniki N; Ojiro K; Yamaguchi A; Morikawa R; Yoshida A; Ikura A; Ebinuma H; Saito H; Kanai T
    BMC Gastroenterol; 2020 Mar; 20(1):53. PubMed ID: 32138675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema.
    Atsukawa M; Tsubota A; Kato K; Abe H; Shimada N; Asano T; Ikegami T; Koeda M; Okubo T; Arai T; Nakagawa-Iwashita A; Yoshida Y; Hayama K; Itokawa N; Kondo C; Chuganji Y; Matsuzaki Y; Iwakiri K
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1256-1263. PubMed ID: 29215154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites.
    Kawaratani H; Moriya K; Namisaki T; Shimozato N; Kaji K; Takaya H; Fujinaga Y; Sawada Y; Sato S; Saikawa S; Kubo T; Akahane T; Fukui H; Yoshiji H
    Exp Ther Med; 2021 Jan; 21(1):30. PubMed ID: 33262816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial.
    Tang J; Wang Y; Han T; Mao Q; Cheng J; Ding H; Shang J; Zhang Q; Niu J; Ji F; Chen C; Jia J; Jiang X; Lv N; Gao Y; Wang Z; Wei Z; Chen Y; Zeng M; Mao Y
    BMC Gastroenterol; 2020 Nov; 20(1):391. PubMed ID: 33213378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    Komiyama Y; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Yasui Y; Tamaki N; Takada H; Higuchi M; Gotou T; Kubota Y; Takaura K; Hayashi T; Oh W; Okada M; Enomoto N; Izumi N
    PLoS One; 2017; 12(3):e0174649. PubMed ID: 28362879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of peritoneovenous shunt for treating tolvaptan-resistant refractory ascites in a cirrhotic patient with portal vein thrombosis: A case report.
    Shigeto K; Kawaguchi T; Niizeki T; Kunitake Y; Takedatsu H; Tonan T; Fujimoto K; Tanaka M; Abe T; Naito H; Torimura T
    Oncol Lett; 2016 May; 11(5):3205-3209. PubMed ID: 27123091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of continued administration of tolvaptan on cirrhotic patients with ascites.
    Kogiso T; Sagawa T; Kodama K; Taniai M; Tokushige K
    BMC Pharmacol Toxicol; 2018 Dec; 19(1):87. PubMed ID: 30563565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.
    Sakaida I; Terai S; Nakajima K; Shibasaki Y; Tachikawa S; Tsubouchi H
    J Gastroenterol; 2017 Feb; 52(2):229-236. PubMed ID: 27379386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites.
    Hosui A; Tanimoto T; Okahara T; Ashida M; Ohnishi K; Wakahara Y; Kusumoto Y; Yamaguchi T; Sueyoshi Y; Hirao M; Yamada T; Hiramatsu N
    J Clin Med; 2021 Jan; 10(2):. PubMed ID: 33466878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites.
    Arase Y; Kagawa T; Tsuruya K; Sato H; Teramura E; Anzai K; Hirose S; Deguchi R; Shiraishi K; Mine T
    Clin Drug Investig; 2019 Jan; 39(1):45-54. PubMed ID: 30284699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
    Kida Y
    Dig Dis; 2019; 37(3):239-246. PubMed ID: 30625470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.
    Sakaida I; Yamashita S; Kobayashi T; Komatsu M; Sakai T; Komorizono Y; Okada M; Okita K;
    J Int Med Res; 2013 Jun; 41(3):835-47. PubMed ID: 23685892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of tolvaptan short-term response in patients with refractory ascites: A meta-analysis.
    Bellos I; Kontzoglou K; Perrea DN
    J Gastroenterol Hepatol; 2020 Feb; 35(2):182-191. PubMed ID: 31323125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):461-70. PubMed ID: 24678622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.